{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:24:05Z","timestamp":1769847845068,"version":"3.49.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.drudis.2019.07.009","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T19:27:47Z","timestamp":1565724467000},"page":"610-619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Immunotherapy for treating methamphetamine, heroin and cocaine use disorders"],"prefix":"10.1016","volume":"25","author":[{"given":"Tang","family":"Xiaoshan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Junjie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Wenqing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng","family":"Yunong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Jiaping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Shanshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandakumar","family":"Kutty Selva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Kui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.07.009_bib0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.15585\/mmwr.mm6712a1","article-title":"Overdose deaths involving opioids, cocaine, and psychostimulants \u2013 United States, 2015\u20132016","volume":"67","author":"Seth","year":"2018","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.drudis.2019.07.009_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drudis.2019.07.009_bib0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use","volume":"9","author":"Kampman","year":"2015","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drudis.2019.07.009_bib0020","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1146\/annurev-pharmtox-010617-052534","article-title":"The opioid epidemic: crisis and solutions","volume":"58","author":"Skolnick","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.drudis.2019.07.009_bib0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra1508490","article-title":"Relationship between nonmedical prescription-opioid use and heroin use","volume":"374","author":"Compton","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2019.07.009_bib0030","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate vaccine immunotherapy for substance use disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drudis.2019.07.009_bib0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.intimp.2016.03.028","article-title":"Optimization of a methamphetamine conjugate vaccine for antibody production in mice","volume":"35","author":"Stevens","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.drudis.2019.07.009_bib0040","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.1021\/jm901134w","article-title":"The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse","volume":"52","author":"Carroll","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.107.134395","article-title":"Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine","volume":"325","author":"Peterson","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2019.07.009_bib0050","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/pro.244","article-title":"Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse \u2013 methamphetamine and 3,4-methylenedioxymethamphetamine","volume":"18","author":"Celikel","year":"2009","journal-title":"Protein Sci."},{"key":"10.1016\/j.drudis.2019.07.009_bib0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1373\/49.1.121","article-title":"Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers","volume":"49","author":"Schepers","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0060","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.4161\/19420862.2014.976431","article-title":"First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers","volume":"6","author":"Stevens","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2019.07.009_bib0065","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1021\/ja108807j","article-title":"Impact of distinct chemical structures for the development of a methamphetamine vaccine","volume":"133","author":"Moreno","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2019.07.009_bib0070","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1021\/acschemneuro.6b00389","article-title":"Influencing antibody-mediated attenuation of methamphetamine CNS distribution through vaccine linker design","volume":"8","author":"Gooyit","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.drudis.2019.07.009_bib0075","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1021\/acs.jmedchem.6b00084","article-title":"Methamphetamine vaccines: improvement through hapten design","volume":"59","author":"Collins","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0080","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1039\/C4CC00682H","article-title":"Lipid tucaresol as an adjuvant for methamphetamine vaccine development","volume":"50","author":"Collins","year":"2014","journal-title":"Chem. Commun."},{"key":"10.1016\/j.drudis.2019.07.009_bib0085","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4049\/jimmunol.158.3.1377","article-title":"Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin","volume":"158","author":"Tempero","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2019.07.009_bib0090","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.molimm.2011.04.014","article-title":"Inhibiting the C5-C5a receptor axis","volume":"48","author":"Woodruff","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.drudis.2019.07.009_bib0095","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.vaccine.2009.02.105","article-title":"Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines","volume":"27","author":"Duryee","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2019.07.009_bib0100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1124\/jpet.106.117150","article-title":"Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse","volume":"322","author":"Peterson","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2019.07.009_bib0105","doi-asserted-by":"crossref","first-page":"12060","DOI":"10.1038\/srep12060","article-title":"A nanotechnology-based platform for extending the pharmacokinetic and binding properties of anti-methamphetamine antibody fragments","volume":"5","author":"Nanaware-Kharade","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.07.009_bib0110","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.4161\/hv.29707","article-title":"Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development","volume":"10","author":"Laurenzana","year":"2014","journal-title":"Hum. Vaccin. Immunother"},{"key":"10.1016\/j.drudis.2019.07.009_bib0115","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1016\/j.vaccine.2009.09.072","article-title":"Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats","volume":"27","author":"Laurenzana","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2019.07.009_bib0120","doi-asserted-by":"crossref","first-page":"e82690","DOI":"10.1371\/journal.pone.0082690","article-title":"Structural characterization of a therapeutic anti-methamphetamine antibody fragment: oligomerization and binding of active metabolites","volume":"8","author":"Peterson","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2019.07.009_bib0125","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1038\/srep03673","article-title":"Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering","volume":"4","author":"Thakkar","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.07.009_bib0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/01.ftd.0000211812.27558.6e","article-title":"Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine","volume":"28","author":"Maurer","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.drudis.2019.07.009_bib0135","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1021\/jm200461m","article-title":"A vaccine strategy that induces protective immunity against heroin","volume":"54","author":"Stowe","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0140","doi-asserted-by":"crossref","first-page":"10776","DOI":"10.1021\/jm301262z","article-title":"Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance","volume":"55","author":"Bremer","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0145","doi-asserted-by":"crossref","first-page":"8601","DOI":"10.1021\/jacs.7b03334","article-title":"Development of a clinically viable heroin vaccine","volume":"139","author":"Bremer","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2019.07.009_bib0150","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.vaccine.2013.04.027","article-title":"Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs","volume":"31","author":"Matyas","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2019.07.009_bib0155","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.vaccine.2014.01.028","article-title":"Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine","volume":"32","author":"Matyas","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2019.07.009_bib0160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/acs.jmedchem.7b01427","article-title":"A stable heroin analogue that can serve as a vaccine hapten to induce antibodies that block the effects of heroin and its metabolites in rodents and that cross-react immunologically with related drugs of abuse","volume":"61","author":"Sulima","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0165","doi-asserted-by":"crossref","first-page":"9036","DOI":"10.1073\/pnas.1219159110","article-title":"Dynamic vaccine blocks relapse to compulsive intake of heroin","volume":"110","author":"Schlosburg","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2019.07.009_bib0170","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/mp400631w","article-title":"Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy","volume":"11","author":"Bremer","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.07.009_bib0175","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1021\/acs.molpharmaceut.7b00933","article-title":"Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality","volume":"15","author":"Hwang","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.07.009_bib0180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/(SICI)1522-2675(19990113)82:1<85::AID-HLCA85>3.0.CO;2-Q","article-title":"Nonenzymatic hydrolysis of cocaine via intramolecular acid catalysis","volume":"82","author":"Li","year":"1999","journal-title":"Helv. Chim. Acta."},{"key":"10.1016\/j.drudis.2019.07.009_bib0185","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/ja400356g","article-title":"Modulating cocaine vaccine potency through hapten fluorination","volume":"135","author":"Cai","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2019.07.009_bib0190","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1021\/jm400228w","article-title":"Probing active cocaine vaccination performance through catalytic and noncatalytic hapten design","volume":"56","author":"Cai","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0195","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1021\/mp400214w","article-title":"Probing the effects of hapten stability on cocaine vaccine immunogenicity","volume":"10","author":"Cai","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.07.009_bib0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biopsych.2009.08.031","article-title":"Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans","volume":"67","author":"Haney","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drudis.2019.07.009_bib0205","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.04.003","article-title":"Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial","volume":"140","author":"Kosten","year":"2014","journal-title":"Drug Alcohol. Depend."},{"key":"10.1016\/j.drudis.2019.07.009_bib0210","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/mt.2010.280","article-title":"Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs","volume":"19","author":"Hicks","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2019.07.009_bib0215","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/npp.2011.200","article-title":"Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects","volume":"37","author":"Wee","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2019.07.009_bib0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1006\/jmbi.2001.4839","article-title":"Crystal structure of a cocaine-binding antibody","volume":"311","author":"Larsen","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.drudis.2019.07.009_bib0225","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1021\/mp200588v","article-title":"An antidote for acute cocaine toxicity","volume":"9","author":"Treweek","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.07.009_bib0230","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1021\/jm030351z","article-title":"Three-dimensional quantitative structure\u2013activity relationship modeling of cocaine binding by a novel human monoclonal antibody","volume":"47","author":"Paula","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0235","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbrc.2017.04.117","article-title":"Characterization of a recombinant humanized anti-cocaine monoclonal antibody produced from multiple clones for the selection of a master cell bank candidate","volume":"487","author":"Wetzel","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2019.07.009_bib0240","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/dmd.114.057034","article-title":"A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats","volume":"42","author":"Norman","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drudis.2019.07.009_bib0245","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.118.253674","article-title":"A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats","volume":"368","author":"Raleigh","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2019.07.009_bib0250","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/anie.201511654","article-title":"Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs","volume":"55","author":"Bremer","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.drudis.2019.07.009_bib0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1021\/acschembio.6b00977","article-title":"An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life","volume":"12","author":"Kimishima","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.drudis.2019.07.009_bib0260","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.vaccine.2012.04.101","article-title":"Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats","volume":"30","author":"Pravetoni","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.drudis.2019.07.009_bib0265","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.8b00592","article-title":"Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins","volume":"15","author":"Baruffaldi","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2019.07.009_bib0270","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3762\/bjoc.15.100","article-title":"A chemically contiguous hapten approach for a heroin-fentanyl vaccine","volume":"15","author":"Natoriti","year":"2019","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0275","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1021\/acs.jmedchem.5b00220","article-title":"Combining active immunization with monoclonal antibody therapy to facilitate early initiation of a long-acting anti-methamphetamine antibody response","volume":"58","author":"Hambuchen","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2019.07.009_bib0280","first-page":"1","article-title":"A conjugate vaccine attenuates morphine- and heroin-induced behavior in rats","volume":"18","author":"Li","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2019.07.009_bib0285","unstructured":"National Institute on Drug Abuse Principles of Drug Addiction Treatment: A Research-Based Guide (3rd edn). Available at: https:\/\/www.drugabuse.gov\/publications\/principles-drug-addiction-treatment-research-based-guide-third-edition\/principles-effective-treatment."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644619303083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644619303083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:42:46Z","timestamp":1761223366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644619303083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1359644619303083"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.07.009","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for treating methamphetamine, heroin and cocaine use disorders","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}